4Takiguchi Y, Moriya T, A saka-Amano Y, et al. Phase Ⅱ study of Weekly irinotecan and cisp latin for refractory or recurrent nonsmall cell lu - ng cancer[J]. Lung Cancer, 2007, 58 (2) : 253 - 259.
8Suzuki S, Harada N, Takeo Y, et al. B i-weekly irinotecan hydro2 ehh, ride and cisp latin as a second-line chemotherapy for patients with advanc ed gastrie cancer[J].Gan To Kagaku Ryoho, 2007,34(13): 2 245 - 2 248.
7Daly MB,Ozols RF. Symptoms of ovarian cancer-where to set the bar? [J].JAMA,2004,291 (22) :2755 -2756.
8Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO- OVAR-2.2 trial[ J]. Lancet,2003,361 (9375) :2099 - 2106.
9Keldsen N, Havsteen H, Vergote I, et al. Ahretamine ( hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer:a phase Ⅱ study[J]. Gynecol Oncol,2003,88(2) :118 - 122.
